Toni Choueiri: PEACE-3 phase 3 trials first results at ESMO24
Katy Beckermann, Assistant Professor Of Medicine, Vanderbilt University Medical Center, shared a post on X by Toni Choueiri adding:
“The RCC TiNivo-2 study may have been overall negative, but it highlighted:
1. CKI shouldn’t continue in IO-refractory disease.
2. Selective VEGF TKIs like tivozanib can have activity in the post-IO setting.
3. TKI dosage matters.”
Quoting Toni Choueiri’s post below:
“Outstanding talk from Silke Gillessen elegantly presenting PEACE-3 phase 3 trials first results.
Adding 6 cycles of Ra223 to enzalutamide as first-line therapy for mCRPC showed significant rPFS improvement and significant OS benefit.”
Source: Toni Choueiri/X and Katy Beckermann/X
Toni Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. He is the Medical Director of International Strategic Initiatives at Dana-Farber and past President of the Medical Staff at DFCI (2016-2018).
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023